ArticleBlood advances2017
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.Annals of hematology · 2022Pooled it
- Trial
- Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.Cell reports. Medicine · 2021Trial
- PD-L1 and tumor-associated macrophages in de novo DLBCL.Blood advances · 2019Trial
- Explainable machine learning identifies features and thresholds predictive of immunotherapy response.Scientific reports · 2026Article
- CD27 expression is a clinically accessible biomarker for predicting immunotherapy response in melanoma.NPJ precision oncology · 2026Article
- PROTAC-based protein degradation: a window of opportunity for melanoma therapy.Journal of biomedical science · 2026Review
- Bendamustine switches TNF receptor superfamily signal from a survival to a death signal in B-cell lymphomas.Blood neoplasia · 2025Article
- Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances.The Korean journal of internal medicine · 2025Review
- Predicting Survival Rates in Brain Metastases Patients from Non-Small Cell Lung Cancer Using Radiomic Signatures Associated with Tumor Immune Heterogeneity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent advances in understanding the biology of follicular lymphoma.International journal of hematology · 2025Review
- MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma.Frontiers in oncology · 2025Article
- Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.Cancer research communications · 2024Article
- Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.Journal for immunotherapy of cancer · 2024Article
- Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.Blood cancer journal · 2024Article
- LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.Clinical and translational medicine · 2023Article
- Translation of AI into oncology clinical practice.Oncogene · 2023Review
- Features of metabolism associated molecular patterns in pancreatic ductal adenocarcinoma.Cancer gene therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical impact of mutation load and an effector T-cell (T
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.